Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer

Clinical Cancer Research

Volumn 9, Issue 11, 2003, Pages 4165-4171

  Hu, Ying Chuan ^a   Komorowski, Richard A ^b   Graewin, Shannon ^b   Hostetter, Galen ^c   Kallioniemi, Olli P ^c,d   Pitt, Henry A ^b   Ahrendt, Steven A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIFFERENTIAL DIAGNOSIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PANCREAS CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE;

EID: 0141678071     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. American Cancer Society. Cancer Facts and Figures 2001, pp. 5-16. Atlanta, GA: American Cancer Society, 2001.
2. Klinkenbijl, J., Jeekel, J., Sahmoud, T., Pei, R. v., Couvreur, M., Veenhof, C., Arnaud, J., Gonzalez, D., Wit, L. d., Hennipman, A., and Wils, J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann. Surg., 230: 776-784, 1999.
3. Yeo, C. J., Abrams, R. A., Grochow, L. B., Sohn, T. A., Ord, S. E., Hruban, R. H., Zahurak, M. L., Dooley, W. C., Coleman, J., Sauter, P. K., Pitt, H. A., Lillemoe, K. D., and Cameron, J. L. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. Ann. Surg., 225: 621-636, 1997.
4. Sohn, T. A., Yeo, C. J., Cameron, J. L., Koniaris, L., Kaushal, S., Abrams, R. A., Sauter, P. K., Coleman, J., Hruban, R. H., and Lillemoe, K. D. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J. Gastrointest. Surg., 4: 567-579, 2000.
5. Neoptolemos, J., Dunn, J., Stocken, D., Almond, J., Link, K., Beger, H., Bassi, C., Falconi, M., Pederzoli, P., Dervenis, C., Fernandez-Cruz, L., Lacaine, F., Pap, A., Spooner, D., Kerr, D., Friess, H., and Buchler, M. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet, 358: 1576-1585, 2001.
6. Abrams, R., Lillemoe, K., and Piantadosi, S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet, 358: 1565-1566, 2001.
7. Neoptolemos, J., Stocken, D., and Dunn, J. Letter. Ann. Surg., 236: 694-696, 2002.
8. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer (Phila.), 59: 2006-2010, 1987.
9. Exocrine pancreas. In: I. Fleming, J. Cooper, D. Henson, R. Hutter, B. Kennedy, G. Murphy, B. O'Sullivan, L. Sobin, and J. Yarbro (eds.), AJCC Cancer Staging Manual, 5th ed., Chapter 18, pp. 121-124. Philadelphia: Lippincott Williams & Wilkins, 1997.
10. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O-P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med., 4: 844-847, 1998.
11. Johnston, P., Fisher, E., Rockette, H., Fisher, B., Wolmark, N., Drake, J., Chabner, B., and Allegra, C. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol., 12: 2640-2647, 1994.
12. Allegra, C. Thymidylate synthase levels: prognostic, predictive, or both? J. Clin. Oncol., 20: 1711-1713, 2002.
13. Kuniyasu, T., Nakamura, T., Tabuchi, Y., and Kuroda, Y. Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer (Phila.), 83: 1300-1306, 1998.
14. Shiga, H., Heath, E., Rasmussen, A., Trock, B., Johnston, P., Forastiere, A., Langmacher, M., Baylor, A., Lee, M., and Cullen, K. Prognostic value of p53, glutathione S-transferase π, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin. Cancer Res., 5: 4097-4104, 1999.
15. Pestalozzi, B., Peterson, H., Gelber, R., Goldhirsch, A., Gusterson, B., Trihia, H., Lindtner, J., Cortes-Funes, H., Simmoncini, E., Byrne, M., Golouh, R., Rudenstam, C., Castiglione-Gertsch, M., Allegra, C., and Johnston, P. Prognostic significance of thymidylate synthase expression in early breast cancer. J. Clin. Oncol., 15: 1923-1931, 1997.
16. Harpole, D., Moore, M., Herndon, J., Aloia, T., D'amico, T., Sporn, T., Parr, A., Linoila, I., and Allegra, C. The prognostic value of molecular analysis in patients treated with trimodality therapy for esophageal cancer. Clin. Cancer Res., 7: 562-569, 2001.
17. Kawakami, K., Omura, K., Kanehira, E., and Watanabe, Y. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res., 19: 3249-3252, 1999.
18. Villafranca, E., Okruzhnov, Y., Dominguez, M., Garcia-Foncillas, J., Azinovic, I., Martinez, E., Illarramendi, J., Arias, F., Martinez-Monge, R., Salgado, E., Angeletti, S., and Brugarolas, A. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol., 19: 1779-1786, 2001.
19. Krajinovic, M., Costea, I., and Chiasson, S. Polymorphism of the thymidylate synthase gene and outcome of acute polymorphic lymphoblastic leukemia. Lancet, 359: 1033-1034, 2002.
20. Takamura, M., Nio, Y., Yamasawa, K., Dong, M., Yamaguchi, K., and Itakura, M. Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. Anticancer Drugs, 13: 75-85, 2002.
21. Johnston, P., Lenz, H., Leichman, C., Danenberg, K., Allegra, C., Danenberg, P., and Leichman, L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal cancer and gastric tumors. Cancer Res., 55: 1407-1412, 1995.
22. Johnston, P., Mick, R., Recant, W., Behan, K., Dolan, M., Ratain, M., Beckman, E., Weichselbaum, R., Allegra, C., and Vokes, E. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J. Natl. Cancer Inst. (Bethesda), 89: 308-313, 1997.
23. Leichman, C., Lenz, H., Leichman, L., Danenberg, K., Baranda, J., Groshen, S., Boswell, W., Metzger, R., Tan, M., and Danenberg, P. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol., 15: 3223-3229, 1997.
24. Etienne, M., Chazal, M., Laurent-Puig, P., Magne, N., Rosty, C., Formento, J., Francoual, M., Formento, P., Renee, N., Chamorey, E., Bourgeon, A., Seitz, J., Delpero, J., Letoublon, C., Pezet, D., and Milano, G. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J. Clin. Oncol., 15: 2832-2843, 2002.
25. Edler, D., Glimelius, B., Hallstrom, M., Jakobsen, A., Johnston, P., Magnusson, I., Ragnhammar, P., and Blomgren, H. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J. Clin. Oncol., 20: 1721-1728, 2002.
26. Yamachika, T., Nakanishi, H., Inada, K., Tsukamoto, T., Kato, T., Fukushima, M., Inoue, M., and Tatematsu, M. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer (Phila.), 82: 70-77, 1998.
27. Takenoue, T., Nagawa, H., Matsuda, K., Fujii, S., Nita, M., Hatano, K., Kitayama, J., Tsuruo, T., and Muto, T. Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann. Surg. Oncol., 7: 193-198, 2000.
28. Allegra, C. J., Parr, A. L., Wold, L. E., Mahoney, M. R., Sargent, D. J., Johnston, P., Klein, P., Behan, K., O'Connell, M. J., Levitt, R., Kugler, J. W., Tirona, M. T., and Goldberg, R. M. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J. Clin. Oncol., 20: 1735-1743, 2002.
29. Aschele, C., Debernardis, D., Tunesi, G., Maley, F., and Sobrero, A. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin. Cancer Res., 6: 4797-4802, 2000.
30. WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer. Surgery, 128: 520-530, 2000.
31. Kastanos, E., Zajac-Kaye, M., Dennis, P., and Allegra, C. Downregulation of p21/WAF1 expression by thymidylate synthase. Biochem. Biophys. Res. Commun., 285: 195-200, 2001.
32. Lenz, H., Hayashi, K., Salonga, D., Danenberg, K., Danenberg, P., Metzger, R., Banerjee, D., Bertino, J., Groshen, S., Leichman, L., and Leichman, C. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin. Cancer Res., 4: 1243-1250, 1998.
33. Mohiuddin, M., Chendil, D., Dey, S., Alcock, R., Regine, W., Mohiuddin, M., and Ahmed, M. Influence of p53 status on radiation and 5-fluorouracil synergy in pancreatic cancer cells. Anticancer Res., 22: 825-830, 2002.
34. Milanes-Yearsley, M., Hammond, M., Pajak, T., Cooper, J., Chang, C., Griffin, T., Nelson, D., Laramore, G., and Pilepich, M. Tissue micro-array: a cost and time-effective method for correlative studies by regional and national cancer study groups. Mod. Pathol., 15: 1366-1373, 2002.
35. Rimm, D., Camp, R., Charette, L., Costa, J., Olsen, D., and Reiss, M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J., 7: 24-31, 2001.
36. Rubin, M., Dunn, R., Strawderman, M., and Pienta, K. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am. J. Surg. Pathol., 26: 312-319, 2002.
37. Nukui, Y., Picozzi, V. J., and Traverso, L. W. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am. J. Surg., 179: 367-371, 2000.